Valion Bio, Inc. — Form SCHEDULE 13D/A
Filed September 3, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
3i, LP purchased 3,004 shares of Valion Bio common stock on September 3, 2026 at $2.8808 per share, representing a transaction value of approximately $8,659. This is a Schedule 13D/A amendment disclosing a new transaction; prior transactions were disclosed in the Original Schedule 13D.
Why this rating
~$8,700 transaction is <0.22% of $4M market cap; routine incremental share purchase by existing shareholder; no control shift or material stake change indicated.
See more from September 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.